| Schedule of financial information regularly reviewed and used by the CODM |
This decision-making process reflects the way in which the financial information is regularly reviewed and used by the CODM to evaluate performance, set operational targets, forecast future financial results, and allocate resources.
|
|
|
|
|
|
|
|
|
Three months ended June 30, |
|
|
2026 |
|
|
2025 |
|
Costs and expenses: |
|
|
|
|
|
Research and development (excluding stock-based compensation) expense: |
|
|
|
|
|
PAH |
$ |
11,681,245 |
|
|
$ |
2,738,794 |
|
Parkinson's disease |
|
— |
|
|
|
42,196 |
|
Other research and development |
|
227,113 |
|
|
|
834,142 |
|
Selling, general and administrative (excluding stock-based compensation) |
|
3,796,627 |
|
|
|
3,366,824 |
|
Change in fair value contingent consideration |
|
— |
|
|
|
(358,420 |
) |
Stock-based compensation expense |
|
5,346,010 |
|
|
|
4,208,742 |
|
Total costs and expenses |
|
21,050,995 |
|
|
|
10,832,278 |
|
Loss from operations |
|
(21,050,995 |
) |
|
|
(10,832,278 |
) |
Other income |
|
1,459,764 |
|
|
|
916,755 |
|
Net loss |
$ |
(19,591,231 |
) |
|
$ |
(9,915,523 |
) |
|
|
|
|
|
|
|
Six months ended June 30, |
|
|
2026 |
|
|
2025 |
|
Costs and expenses: |
|
|
|
|
|
Research and development (excluding stock-based compensation) expense: |
|
|
|
|
|
PAH(1) |
$ |
20,298,800 |
|
|
$ |
12,069,638 |
|
Parkinson's disease |
|
— |
|
|
|
184,616 |
|
Other research and development |
|
658,008 |
|
|
|
1,421,270 |
|
Selling, general and administrative (excluding stock-based compensation) |
|
7,403,684 |
|
|
|
7,027,106 |
|
Change in fair value contingent consideration |
|
(373,354 |
) |
|
|
(1,523,284 |
) |
Stock-based compensation expense |
|
10,905,776 |
|
|
|
6,250,938 |
|
Total costs and expenses |
|
38,892,914 |
|
|
|
25,430,284 |
|
Loss from operations |
|
(38,892,914 |
) |
|
|
(25,430,284 |
) |
Other income |
|
2,920,843 |
|
|
|
1,836,026 |
|
Net loss |
$ |
(35,972,071 |
) |
|
$ |
(23,594,258 |
) |
(1) The six months ended June 30, 2025 figure includes a one-time (non-cash) charge of $7.4 million for the acquired IPR&D related to the CorHepta acquisition.
|